General Information:

Id: 6,206
Diseases: Burkitt lymphoma - [OMIM]
Cancer
Homo sapiens
article/cited
Reference: Dong LH et al.(2013) Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma J Hematol Oncol 6: 53 [PMID: 23866964]

Interaction Information:

Comment The HDAC inhibitor VPA (valproic acid) overcomes MTOR inhibitor rapamycin resistance by inhibiting AKT via HDAC3 and potentiates autophagy through down-regulation of MTOR pathway.
Formal Description
Interaction-ID: 57887

drug/chemical compound

Valproic acid

decreases_activity of

gene/protein

HDAC3

Drugbank entries Show/Hide entries for Valproic acid or HDAC3
Comment VPA (valproic acid) reduced HDAC3 activity and subsequently inhibited AKT phosphorylation induced by temsirolimus.
Formal Description
Interaction-ID: 58400

drug/chemical compound

Valproic acid

decreases_phosphorylation of

gene/protein

AKT1

if AKT phosphorylation is induced by temsirolimus.
Drugbank entries Show/Hide entries for Valproic acid or AKT1
Comment Temsirolimus (an MTOR inhibitor) can induce autophagy in lymphoma cells.
Formal Description
Interaction-ID: 58401

drug/chemical compound

Temsirolimus

increases_activity of

process

autophagy

in lymphoma cells.
Drugbank entries Show/Hide entries for Temsirolimus
Comment The HDAC inhibitor VPA and the MTOR inhibitor temsirolimus, both at a clinically achievable concentration, interacted synergistically to inhibit BL (Burkitt leukemia/lymphoma) cell growth.
Formal Description
Interaction-ID: 58402

drug/chemical compound

Valproic acid / Temsirolimus combination

decreases_activity of

disease

Burkitt lymphoma

Comment Valproic acid (VPA), either alone or in combination, inhibited HDAC1 expression, in parallel with decreased HDAC1 enzymatic activity, but increased CDKN1A and CDKN1B expression.
Formal Description
Interaction-ID: 58403

drug/chemical compound

Valproic acid

decreases_expression of

gene/protein

HDAC1

Drugbank entries Show/Hide entries for Valproic acid or HDAC1
Comment The BL (Burkitt leukemia/lymphoma) oncoprotein MYC is the key regulatory element by MTOR pathway.
Formal Description
Interaction-ID: 58405

gene/protein

MYC

increases_activity of

disease

Burkitt lymphoma

Comment The HDAC inhibitor VPA (valproic acid) overcomes MTOR inhibitor rapamycin resistance by inhibiting AKT via HDAC3 and potentiates autophagy through down-regulation of MTOR pathway.
Formal Description
Interaction-ID: 58406

drug/chemical compound

Valproic acid

decreases_activity of

gene/protein

AKT1

via HDAC3
Drugbank entries Show/Hide entries for Valproic acid or AKT1
Comment The HDAC inhibitor VPA (valproic acid) overcomes MTOR inhibitor rapamycin resistance by inhibiting AKT via HDAC3 and potentiates autophagy through down-regulation of MTOR pathway.
Formal Description
Interaction-ID: 58407

drug/chemical compound

Valproic acid

increases_activity of

process

autophagy

through down-regulation of MTOR pathway.
Drugbank entries Show/Hide entries for Valproic acid
Comment The HDAC inhibitor VPA (valproic acid) overcomes MTOR inhibitor rapamycin resistance by inhibiting AKT via HDAC3 and potentiates autophagy through down-regulation of MTOR pathway.
Formal Description
Interaction-ID: 58408

drug/chemical compound

Valproic acid

decreases_activity of

process

TOR signaling

Drugbank entries Show/Hide entries for Valproic acid
Comment VPA (valproic acid) reduced HDAC3 activity and subsequently inhibited AKT phosphorylation induced by temsirolimus.
Formal Description
Interaction-ID: 58409

drug/chemical compound

Temsirolimus

increases_phosphorylation of

gene/protein

AKT1

Drugbank entries Show/Hide entries for Temsirolimus or AKT1
Comment Temsirolimus (an MTOR inhibitor) can induce autophagy in lymphoma cells.
Formal Description
Interaction-ID: 58410

drug/chemical compound

Temsirolimus

decreases_activity of

gene/protein

MTOR

Drugbank entries Show/Hide entries for Temsirolimus or MTOR
Comment Valproic acid (VPA), either alone or in combination, inhibited HDAC1 expression, in parallel with decreased HDAC1 enzymatic activity, but increased CDKN1A and CDKN1B expression.
Formal Description
Interaction-ID: 58411

drug/chemical compound

Valproic acid

decreases_activity of

gene/protein

HDAC1

Drugbank entries Show/Hide entries for Valproic acid or HDAC1
Comment Valproic acid (VPA), either alone or in combination, inhibited HDAC1 expression, in parallel with decreased HDAC1 enzymatic activity, but increased CDKN1A and CDKN1B expression.
Formal Description
Interaction-ID: 58412

drug/chemical compound

Valproic acid

increases_expression of

gene/protein

CDKN1A

Drugbank entries Show/Hide entries for Valproic acid
Comment Valproic acid (VPA), either alone or in combination, inhibited HDAC1 expression, in parallel with decreased HDAC1 enzymatic activity, but increased CDKN1A and CDKN1B expression.
Formal Description
Interaction-ID: 58413

drug/chemical compound

Valproic acid

increases_expression of

gene/protein

CDKN1B

Drugbank entries Show/Hide entries for Valproic acid
Comment The BL (Burkitt leukemia/lymphoma) oncoprotein MYC is the key regulatory element by MTOR pathway.
Formal Description
Interaction-ID: 58414

process

TOR signaling

affects_activity of

gene/protein

MYC

Comment VPA combined with temsirolimus significantly increased CDKN1A and CDKN1B, decreased p-AKT, p-MTOR and MYC oncoprotein.
Formal Description
Interaction-ID: 58415

drug/chemical compound

Valproic acid

increases_activity of

drug/chemical compound

Temsirolimus

Drugbank entries Show/Hide entries for Valproic acid or Temsirolimus
Comment VPA combined with temsirolimus significantly increased CDKN1A and CDKN1B, decreased p-AKT, p-MTOR and MYC oncoprotein.
Formal Description
Interaction-ID: 58416

drug/chemical compound

Temsirolimus

increases_activity of

drug/chemical compound

Valproic acid

Drugbank entries Show/Hide entries for Temsirolimus or Valproic acid